"Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," Lilly spokeswoman Molly McCully said in an emailed statement. "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study."Lilly shares were down about 3% at $150.
Eli Lilly coronavirus antibody trial paused for potential safety concern
By REUTERS
05/08/2024 09:01 AM
By REUTERS
05/08/2024 08:47 AM
By REUTERS
05/08/2024 06:08 AM
By THE MEDIA LINE STAFF
05/08/2024 03:54 AM
By REUTERS
05/08/2024 12:47 AM
By MAARIV
05/07/2024 11:44 PM
By MAARIV
05/07/2024 11:39 PM
By REUTERS
05/07/2024 11:17 PM
By REUTERS
05/07/2024 02:58 PM